Principal Securities’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$21.3M Buy
23,156
+1,851
+9% +$1.88M 0.31% 58
2025
Q4
$22.9M Buy
21,305
+1,855
+10% +$1.77M 0.35% 54
2025
Q3
$14.8M Buy
19,450
+302
+2% +$225K 0.24% 74
2025
Q2
$14.9M Buy
19,148
+1,241
+7% +$964K 0.28% 67
2025
Q1
$13.8M Buy
17,907
+56
+0.3% +$46.6K 0.31% 63
2024
Q4
$13.8M Buy
17,851
+2,662
+18% +$2.2M 0.31% 62
2024
Q3
$13.5M Buy
15,189
+1,027
+7% +$923K 0.33% 57
2024
Q2
$12.8M Buy
14,162
+2,651
+23% +$2.12M 0.35% 51
2024
Q1
$8.96M Buy
11,511
+2,823
+32% +$2.01M 0.28% 72
2023
Q4
$5.06M Buy
+8,688
New +$5.07M 0.19% 110

Other funds holding LLY

Principal Securities's LLY Position: Q1 2026 in Review

Principal Securities increased its Eli Lilly (LLY) stake by 8.7% in Q1 2026, buying an estimated $1.88M and bringing the position to 23,156 shares worth $21.3M. The position accounts for 0.31% of the portfolio, ranked #58.

Principal Securities first reported a position in LLY in Q4 2023 and has held it in 10 quarters since. The position peaked at $22.9M in Q4 2025. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Principal Securities held 23,156 shares of Eli Lilly worth $21.3M as of Q1 2026.
  • Principal Securities bought 1,851 Eli Lilly shares in Q1 2026, an estimated $1.88M.
  • Eli Lilly made up 0.31% of Principal Securities's portfolio in Q1 2026, its #58 holding.
  • Principal Securities first reported a position in Eli Lilly in Q4 2023 and has held it in 10 quarters since.
  • Principal Securities's Eli Lilly position peaked at $22.9M in Q4 2025.
  • 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Principal Securities's 13F filing for Q1 2026, filed 13 May 2026.